- Despite its growing revenue, the company underperformed as compared with the industry average of 4.3%. Since the same quarter one year prior, revenues slightly increased by 3.9%. This growth in revenue does not appear to have trickled down to the company's bottom line, displayed by a decline in earnings per share.
- The current debt-to-equity ratio, 0.34, is low and is below the industry average, implying that there has been successful management of debt levels. To add to this, JNJ has a quick ratio of 1.88, which demonstrates the ability of the company to cover short-term liquidity needs.
- The gross profit margin for JOHNSON & JOHNSON is currently very high, coming in at 72.40%. Regardless of JNJ's high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, JNJ's net profit margin of 1.30% is significantly lower than the same period one year prior.
- The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Pharmaceuticals industry. The net income has significantly decreased by 88.8% when compared to the same quarter one year ago, falling from $1,942.00 million to $218.00 million.
- Net operating cash flow has declined marginally to $3,451.00 million or 9.75% when compared to the same quarter last year. In conjunction, when comparing current results to the industry average, JOHNSON & JOHNSON has marginally lower results.
TheStreet Ratings Top 10 Rating Changes
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts